These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33939146)

  • 1. Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.
    Mohamed FEZ; Jalan R; Minogue S; Andreola F; Habtesion A; Hall A; Winstanley A; Damink SO; Malagó M; Davies N; Luong TV; Dhillon A; Mookerjee R; Dhar D; Al-Jehani RM
    Dig Dis Sci; 2022 May; 67(5):1806-1821. PubMed ID: 33939146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.
    Mohamed FE; Al-Jehani RM; Minogue SS; Andreola F; Winstanley A; Olde Damink SW; Habtesion A; Malagó M; Davies N; Luong TV; Dhillon AP; Mookerjee RP; Dhar DK; Jalan R
    Liver Int; 2015 Mar; 35(3):1063-76. PubMed ID: 24990399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune responses after stimulation with Toll-like receptor agonists in ex vivo microglial cultures and an in vivo model using mice with reduced microglia.
    Carroll JA; Race B; Williams K; Striebel JF; Chesebro B
    J Neuroinflammation; 2021 Sep; 18(1):194. PubMed ID: 34488805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
    Butchi NB; Du M; Peterson KE
    Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
    Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
    Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma.
    Sheyhidin I; Nabi G; Hasim A; Zhang RP; Ainiwaer J; Ma H; Wang H
    World J Gastroenterol; 2011 Aug; 17(32):3745-51. PubMed ID: 21990957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
    Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
    Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
    Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR4, TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis: relationship with clinical characteristics.
    Matsushita H; Miyake Y; Takaki A; Yasunaka T; Koike K; Ikeda F; Shiraha H; Nouso K; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):600-8. PubMed ID: 25160604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.
    Berghöfer B; Haley G; Frommer T; Bein G; Hackstein H
    J Immunol; 2007 Apr; 178(7):4072-9. PubMed ID: 17371961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.
    Haas F; Yamauchi K; Murat M; Bernasconi M; Yamanaka N; Speck RF; Nadal D
    J Virol; 2014 Sep; 88(17):10002-12. PubMed ID: 24942583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
    Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
    PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses.
    Pone EJ; Lou Z; Lam T; Greenberg ML; Wang R; Xu Z; Casali P
    Autoimmunity; 2015 Feb; 48(1):1-12. PubMed ID: 25536171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.
    Wu J; Li S; Li T; Lv X; Zhang M; Zang G; Qi C; Liu YJ; Xu L; Chen J
    J Immunol Res; 2019; 2019():1749803. PubMed ID: 31093508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of human B cell activation by TLR7 and TLR9 agonists.
    Hanten JA; Vasilakos JP; Riter CL; Neys L; Lipson KE; Alkan SS; Birmachu W
    BMC Immunol; 2008 Jul; 9():39. PubMed ID: 18652679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Immunosuppressive Effects of CpG-c41 on Intracellular TLR-Mediated Inflammation.
    Liu W; Yang X; Wang N; Fan S; Zhu Y; Zheng X; Li Y
    Mediators Inflamm; 2017; 2017():6541729. PubMed ID: 28539706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-Wide ChIP-seq and RNA-seq Analyses of STAT3 Target Genes in TLRs Activated Human Peripheral Blood B Cells.
    Wu J; Jin YY; Gong RL; Yang F; Su XY; Chen TX
    Front Immunol; 2022; 13():821457. PubMed ID: 35345674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.